Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
VBL Therapeutics is a late-stage clinical biopharmaceutical company focused on the development of cancer treatments. VBL's clinical pipeline is based on two proprietary platforms that leverage the body's natural physiologic and genetic regulatory elements. VBL has developed an oncology program and an anti-inflammatory program based on these platforms. The company's lead candidate, VB-111, is a gene-based biologic for recurrent glioblastoma (rGBM). Phase 2 interim data show an overall survival benefit for VB-111 in rGBM, providing proof-of-concept, with a high level of safety and tolerability. VB-111 has received orphan drug designation in the United States and Europe and was granted Fast Track designation by the FDA for prolongation of survival in patients with rGBM. VBL Therapeutics plans to begin Phase 3 clinical trial of VB-111 in rGBM under a special protocol assessment agreement granted by the FDA. VBL's oncology program is based on its proprietary Vascular Targeting System platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. VBL has also developed a proprietary platform of small molecules, Lecinoxoids, for the treatment of chronic immune-related indications.